CAPSULE PRODUCTION AND VIRULENCE AMONG STRAINS OF STAPHYLOCOCCUS AUREUS by Wiley, Bill B. & Maverakis, Nick H.
CAPSULE PRODUCTION AND VIRULENCE AMONG 
STRAINS OF STAPHYLOCOCCUS AUREUS 
Bill B. Wiley 
Department of Microbiology 
University of Utah College of Medicine 
Salt Lake City, Utah 84112 
N. H. Maverakis 
Department of Epidemiology 
University of Michigan School of Public Health 
Ann Arbor, Michigan 48104 
In 1956, just after Price and Kneelandl first reported the occurrence of a 
specific capsular reaction in a strain of mucoid S .  aureus isolated after egg 
passage of a throat isolate with an A strain of influenza virus, we were searching 
about for an area of endeavor that might interest us. Their initial report was 
followed by a second one in which they seemed to downgrade the importance 
of their finding by reporting what they interpreted as a lack of specificity, 
owing to the fact that all of 39 isolates of S .  aureus from clinical material 
exhibited specific capsular reactions with a single antiserum. We could not agree 
with their conclusion; this proved to be the stimulus that awakened our interest 
in the occurrence of encapsulation and its significance among strains of S. 
aureus. 
Our first efforts in the field were concerned with the isolation of mucoid 
variants of S. aureus; we employed the technique of Bigger and colleagues.:: 
They cultivated staphylococci in broth that contained a fermentable carbohy- 
drate, and maintained the cultures in this environment for up to two months. 
Periodic subcultivation to agar plates and subsequent testing of colonies for 
mucosity was used as a screening proceduce to obtain mucoid variants. With 
this procedure we obtained five mucoid strains of S.  aureus. One strain, 
which originated from an infected sutured wound, was especially mucoid and 
was used to stimulate antibody production in rabbits and roosters. A long and 
vigorous immunization course was used, as described by Alexander and col- 
leagues for the production of antiserum for use in the specific capsular reaction 
with Haetnophilus influenzae. A positive specific capsular reaction obtained 
with the rooster hyperimmune serum and a negative reaction are shown in 
FIGURES 1A and 1B respectively. 
A tendency to decry the finding of capsules on mucoid variants of S.  aureus 
obtained by laboratory manipulation led to studies of the incidence of naturally 
occurring strains of encapsulated S.  nureus and the natural occurrence of anti- 
capsular antibodies. Healthy human blood donors from a rural area submitted 
to swabbing of their anterior nares and also donated samples of their plasma. 
The swabs were planted on mannitol salt plates and colonies were picked and 
placed in buffered nutrient glycerol broth for subsequent testing in the specific 
capsular reaction, in which we used a hyperimmune rabbit antistaphylococcus 
serum. We used the plasma samples of the donors in a specific capsular reaction 
test, using the known encapsulated S. aureus we had isolated. The results of 
these tests are shown in TABLE 1. Of the 109 blood donors, 43% carried S .  
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TABLE 1
INCIDENCE OF STAPHYLOCOCCUS CARRIERS AMONG 109 BLOOD DONORS 
Number Percentage 
Nasal carriers 47 43 
Carriers with encapsulated staphylococci * 21 44.7 
Carriers with nonencapsulated staphylococci -i- 26 55.3 
* This was determined by production of a positive specific capsular reaction, using 
t This was determined by failure of rooster antiwound S .  aureus serum to produce 
rooster antiwound S. aureus serum. 
a positive specific capsular reaction. 
aureus in their anterior nares. Of these staphylococcus carriers, 44.7% carried 
naturally occurring encapsulated S. aureus; this was evidenced by the positive 
specific capsular reactions they exhibited. The remaining 55.3% of the carriers 
carried either nonencapsulated S. aureus or encapsulated strains of different 
capsular types for which we had no antiserum. TABLE 2 presents the results of 
specific capsular reaction tests carried out on the serum of the blood donors. 
The incidence of anticapsular antibodies that reacted against the wound encap- 
sulated strain of S. aureus was 80%. Of the 47 donors who carried S. aureus, 
37 (78.7% ) had anticapsular antibodies. Of the staphylococcus carriers in the 
study, 21.3% did not have anticapsular antibodies against the wound encapsu- 
lated S. aureus. Since such a high incidence of naturally occurring anticapsular 
antibodies had been revealed, it was decided to study a group of 50 sera from 
pediatric subjects that had originally been submitted for viral studies. The 
subjects ranged in age from 1 month to 13 years. None of the subjects 6 years 
old or under had anticapsular antibodies. As further confirmation of the high 
TABLE 2 
INCIDENCE OF STAPHYLOCOCCAL ANTICAPSULAR ANTIBODIES IN 109 BLOOD DONORS 
Precentage of Percentage of 
Number Blood Donors Carriers 
Carriers with capsular 
Carriers without capsular 
Noncarriers with capsular 
Noncarriers without capsular 
Total number of donors 
antibodies * 37 34 
antibodies * 10 9 
antibodies * 50 46 
antibodies .t 12 11 




xz Numbers and percentages represent positive specific capsular reactions obtained 
t This was determined by failure of the donor’s serum to elicit a positive specific 
using the mucoid wound encapsulated S.  aureus and donor’s serum. 
capsular reaction using the wound mucoid encapsulated S.  aureus. 
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incidence of anticapsular antibodies in humans that reacted with the wound 
encapsulated strain, a group of 173 cord blood specimens submitted to the 
hematology division was examined, and a 48% incidence of anticapsular anti- 
bodies was found. 
of virulence in embryonated hens’ eggs, inspired by studies of 
Frappier and Sonea,6 was developed to study the virulence of naturally occur- 
ring encapsulated S. nureus strains. The test utilized intravenous injection of 
the eggs and an observation period of 5 days. The virulence of a group of 
naturally occurring encapsulated S. aureus strains from healthy carriers and a 
group of naturally encapsulated strains from hospitalized patients were com- 
pared in the virulence test. The results are shown in TABLE 3. The LD,,s were 
calculated by the method of Miller and Tainter,’ and are expressed as the 
numbers of staphylococci that produced a 50% kill after a 5-day observation 
period. The 95% confidence limits, based on a normal distribution, are also 
shown. Within the groups differences in LD,,, were observable, but with the 
exception of the carrier strain P-28, there were no significant differences in 
virulence between the groups. The latter strain was heavily encapsulated and 
significantly more virulent than any of the other strains of S. nureus. The results 
showed the test of virulence in embryonated eggs to be a highly sensitive 
indicator of staphylococcal virulence. 
There was a tendency for cultures of the original wound encapsulated strain 
to give rise to spontaneous nonmucoid variants, and these afforded an excellent 
opportunity to compare subjectively the capsular size as revealed in the specific 
capsular reaction and that of the parent organism, and to compare the egg 
virulence of the parent and the nonmucoid variant. In 4-hour broth cultures 
of the parent strain, capsules were well developed and well maintained by the 
A test 
TABLE 3 
LDss AND PHAGE PATTERNS OF HOSPITAL S. auras STRAINS 
FROM CARRIERS AND PATIENTS 
95 % Confidence Phage 
Strain Source d l  Limits Pattern LD- h 
P-28 carrier 14 1-24 nontypable 
L-35 1,289 759-2,188 53/11 
1,719 1,024-3,09 1 11/81 
2,819 1,863-4,266 52/52A/80/82 





F-32 58,890 29,520- 101,200 3A 
56,240 30,200-104,800 52A/80/82 
S-14 patient 955 501-1,820 1/428/53/54/77/81/82 
P-13 1,000 531-1,863 80/81/82 
D-1 1,259 776-2,042 80/81/82 
c-I 1,936 1,349-2,952 82/3C 
A-I8 8,512 6,026-1 2,030 41/53/11 
K-21 
21,880 14,660-33,120 6/41 / 54 
60,260 29,520-.123,100 1/41/54/15/11 
M-5 
LDss and 95% confidence limits are expressed as the number of organisms that 
produced a 50% kill after a 5-day observation period. 
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TABLE 4
LDsos OF Mucoro AND NONMUCOID VARIANTS 
95% Confidence 
Strain LDm" Limits 
Wound mucoid 250 f 188 
Wound nonmucoid 10,000 k 8,280 
P-28 1 1  r t 6  
P-28 grown in 5% antiserum 60 jl: 28 
LD,s and 95% confidence limits are expressed as the number of organisms that 
produced a 50% kill after a 5-day observation period. 
organisms, while capsules on the nonmucoid variant were small fragmentary 
structures that disappeared spontaneously by 12 hours. Carrier strain P-28 also 
exhibited large capsules in the specific capsular reaction, and was the most 
virulent strain of S. aureus that we had isolated to date. It was decided to 
study the egg virulence of the mucoid wound and nonmucoid variant strains, 
and also to study the effect of growing an encapsulated variant in the presence 
of 5% capsular antiserum. It was assumed that the latter step would suppress 
capsule formation, which would possibly lead to the isolation of a nonencapsu- 
lated variant. Only the highly virulent strain P-28 was subjected to the anti- 
serum treatment. The LD,, figures for these strains in embryonated hens' eggs 
are shown in TABLE 4. The egg virulence of the wound mucoid and nonmucoid 
variant differed significantly. Similarly, the effect of growth in 5% antiserum 
on strain P-28 was to decrease its virulence for embryonated eggs significantly. 
To assess the relationship between capsular size, the amount of capsular 
material synthesized, and egg virulence, a technique used by Ehrenworth and 
Baer in studies of the pathogenicity of Klebsiella pneurnoniae was used. Four 
naturally occurring encapsulated S. aureus strains were studied: specific cap- 
sular reactions were carried out on these strains at 0, 4, 12, and 24 hours after 
inoculation into broth. At the same intervals viable counts and packed cell 
volumes were determined. Egg virulence tests were also done on 24-hour 
cultures of these same strains. The results of the specific capsular reactions 
and the viable count:packed cell volume ratios are presented in TABLE 5. A 
low ratio reflects a large packed cell volume relative to the viable count, and 
thus the presence of large capsules on the cells. As the ratio increases, it reflects 
a lower packed cell volume relative to the viable count, and thus smaller 
capsules. The subjective reading of the specific capsular reaction correlates 
well with the ratios. Strain K-1 had a relatively high ratio initially, reflecting 
its small capsules, which seemed however to increase in size after 12 hours in 
the growth cycle. Strains WSCV and NB-1 were alike in possessing small 
capsules that were maintained for 4-8 hours, then tended to decrease. Strain 
P-28 had a low initial viable count:packed cell volume ratio; this reflected its 
large capsules, which were maintained well for 12 hours. The amount of 
capsular material released into the medium was estimated as a function of 
time by a hemagglutination inhibition test 9 capable of detecting 2-4 pg cap- 
sular material. Strain P-28 liberated the most capsular material, which possibly 
showed that it had a higher rate of synthesis, since it maintained its capsules 
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TABLE 5 
VIABLE COUNT:PACKED CELL VOLUME RATIOS AND RELEASE 
OF CAPSULAR MATERIAL 
Viable 
Count:Packed 
Cell Volume Capsular Specific 
Ratio x Material Capsular 
Strain Time 10" * Released t Reaction t 
hours ag/ml 
0 1 +  0 
4 198 0 1 +  
K- 1 8 303 0 2+ 
12 358 0 2+ 
24 364 100 2 +  
0 1 +  0 
4 187 0 1 +  
Wound SCV 8 43 8 0 1 +  
12 461 0 1 +  
24 373 133 1 +  
0 1+ 0 
4 265 0 1 +  
NB-1 8 348 0 2+ 
12 332 0 1 +  
24 539 80 1 +  
0 4 +  0 
4 33 40 3+  
P-28 8 167 66 2+ 
12 236 133 2 +  





* Packed cell volumes were measured after centrifugation for 30 min at 1000 x g 
t Capsular material was estimated by means of a hemagglutination inhibition test 
$ Specific capsular reaction was tested with rooster anti-wound S. aureus serum. 
in an International Centrifuge Model SBV with number 233 head. 
described in Reference 9. 
well for up to 12 hours, whereas the others did not. These findings correlated 
with the results of the egg virulence tests carried out on these strains (TABLE 6). 
Strain K-1 was the least virulent, while strains WSCV and NB-1 were of inter- 
mediate virulence and strain P-28 was the most virulent of the group. Co- 
agulase titrations correlated with virulence: strain P-28 produced the most free 
coagulase and K-1 the least. Although admittedly the cultures were not grown 
in the presence of increased CO,, there were differences in the amount of rabbit 
red cell lysin elaborated by the various strains. Strain K-1, the least virulent, 
produced the highest titer of lysin active on rabbit red cells, while the other 
strains produced little or no rabbit red cell lysin. 
Virulence tests carried out with strains of S. epiderrnidis were often inde- 
terminate, because the embryonated eggs resisted up to 8 million intravenously 
injected cells. A rather unusual staphylococcal strain, designated as 3961, was 
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coagulase-negative but occasionally exhibited capsules. Whether or not this 
strain was S. epidermidis or S.  aureus was not established. It did not kill em- 
bryonated eggs when administered in high doses, but it could on occasion be 
cultured from injected eggs 5 days after inoculation. The pressure of other 
matters did not permit a thorough investigation of the behavior of this strain; 
perhaps one day we will return to studies of its behavior. 
Since we had developed the egg virulence test,5 it seemed logical to attempt 
to evaluate the passive protective properties of serum that contained specific 
capsular antibodies. We simply modified the virulence test by running culture 
diluted in b,oth simultaneously with culture similarly diluted in antiserum. 
Thus, if the first dilution of the LD,,, was 1 :500 in broth, for the protection 
test we diluted culture 1 : 100 in broth, and the final dilution of 1 :500 was 
made in antiserum. One of the reasons that we did the test this way was our 
desire to keep the injection volume of .05 mi constant. Furthermore, it was 
considered unwise to traumatize the embryos further by attempting to 
preinject antiserum intravenously before giving the challenge inoculum. A 
great deal of difficulty was encountered initially with nonspecific deaths in the 
embryonated eggs, due to hemorrhages. It was later surmised that these could 
be occurring as a result of the activation of permeases in the antiserum through 
dilution after injection. When the sera were heated or globulin fractions were 
prepared from them, the nonspecific death rate fell to an acceptable 5 % .  The 
results are shown in TABLE 7. The data shown have supported the conclusion 
that antisera that contain capsular antibodies do passively protect the embryo- 
nated egg significantly against up to 50 LD,, doses of encapsulated S.  aureus. 
It should be pointed out that the actual amount of antiserum injected per egg 
was .04 ml undiluted serum. To ascertain whether or not polysaccharide frac- 
tions prepared from culture supernatant fluids were capable of removing the 
passive protective properties of the antisera, absorption tests were carried out 
in which these crude polysaccharide fractions isolated after ethanol precipitation 
were used. TABLE 8 shows the results of this experiment: the polysaccharide 
fractions significantly removed protective properties from rabbit immune globu- 
lin and human globulin. 
Up to this point, all of the work had been done with the wound mucoid 
strain of encapdated S.  aureus. Our laboratory showed that the wound mucoid 
strain and the RLM strain first described by Price and Kneelandl were of the 
same capsular type, when we succeeded in producing a specific capsular reaction 
TABLE 6 
LD,s OF NATURALLY ENCAPSULATED S. aureus STRAINS 
Strain 
95% Confidence 
LD M ’: Limits 
K- 1 






1 1  
& 22,204 
-+ 3,024 * 2,220 
- c 6  
* LDws and 95% confidence h i t s  are expressed as the number of organisms that 
produced a 50% kill after a 5-day observation period. 
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TABLE 7 
PASSIVE PROTECTIVE PROPERnES OF CAPSULAR ANTIBODY 
Number of 
LDms Used Percent 
Antiserum in Challenge Survival 
None 
Normal rabbit globulin 
Immune rabbit globulin 
None 
Normal rabbit globulin 
Immune rabbit globulin 
None 
Normal rabbit globulin 



















:& A wound mucoid strain of S .  aureus was used. 
of the RLM strain with an antiserum against the wound strain. It seemed that 
the results and conclusions of Price and Kneeland 1, 2 had been confirmed; still, 
we were not ready to conclude that a lack of specificity existed in the capsular 
antigen simply because all isolates seemed to be of a single type. We concluded 
instead that the wound-RLM type possibly represented a major capsular type, 
owing to the widespread occurrence of this type and of antibodies against it in 
various animal and human sera. In 1968 lo we described the paradoxical be- 
havior of two encapsulated variants of S. aurew in mice. One of the variants, 
the wound strain with which most of our work had been done, was indisputably 
encapsulated. The other, the Smith diffuse variant, was held to be encapsulated 
by virtue of its appearance in wet mounts of India ink and its extraordinary 
virulence for mice. It had never, however, exhibited a positive specific capsular 
reaction. We definitively established that the Smith variant was encapsulated, 
because it produced a positive specific capsular reaction in the presence of 
TABLE 8 




Immune rabbit globulin 
Absorbed immune rabbit globulin 
None 
Human globulin 
Absorbed human globulin 
None 
Immune rabbit globulin 








8 0  
10 
r:i A wound mucoid strain of S. aureus was used. 
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TABLE 9
SPECIFIC APSULAR EACTIONS OF STAPHYLOCOCCI :> 
Antiserum Prepared Against 
Strain Encapsulated Wound Smith Strain 
~~~~~ ~ ~ ~ 
- 
- Wound + Wound SCV - + Smith diffuse - 
Smith compact - - 
:* Tests were carried out with hyperimmune rooster anti-S. aurerrs serum. 
hyperimmune rooster serum. The conditions under which this reaction is elicited 
with the Smith diffuse variant differ from those under which it occurs with the 
wound strain. The latter strain exhibits capsules optimally in 4- to 8-hour broth 
cultures, while the Smith diffuse variant does so in 18-hour plate cultures. 
Attempts to produce specific capsular reactions with heterologous sera produced 
the results shown in TABLE 9. The antisera produced specific capsular reactions 
only with the homologous strains; thus, it seemed reasonable to postulate that 
these were two serologically distinct capsular types. These two capsular types 
behaved differently in virulence tests carried out in mice when hog gastric 
mucin was used as a virulence enhancer; the results of these tests are shown in 
TABLE 10. The Smith diffuse variant was virulent in Swiss albino mice, whereas 
the wound encapsulated variant was not. We postulated the carriage of encap- 
sulated S. nureus by mice as a possible explanation of the anomalous behavior 
of the two strains. Throat and rectal swabs from mice yielded coagulase- 
positive S. aureus from 61.5% of 60 mice, making a total of 45 S. nureus 
strains. Two of the strains isolated were found to be naturally encapsulated 
and of the wound type, so the mouse sera were examined to ascertain the 
incidence of capsular antibodies. The results of this examination are shown 
in TABLE 11: 55% of the mice had capsular antibodies against the wound 
encapsulated strain. This prompted an examination of 40 additional mouse 
sera, in order to ascertain the simultaneous incidence of wound and Smith 
capsular antibodies in the same mouse (TABLE 12).  The table shows that none 
of the 40 mice appeared to have Smith capsular antibodies, whereas 32.5% 
had wound anticapsular antibodies. We postulated that the behavior of the 
two encapsulated strains in Swiss albino mice was due to the lack of resistance 
to the Smith diffuse variant and the presence of a high degree of resistance to 
TABLE 10 
LD,, ESTIMATIONS OF ENCAPSULATED S. nrireus IN MICE 
Strain LD Xl :> 95% Confidence Limits 
Smith diffuse 12 4-3 2 
Wound mucoid 550,000 350,000-850,000 
: LDas and 95% confidence limits are expressed as the number of staphylococci 
necessary to produce a 50% kill, calculated after a 14-day observation period. 
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TABLE 11 
INCIDENCE OF CAPSULAR ANTIBODIES IN MICE * 
Test Strain Number Positive Percentage 
Wound mucoid * 





* This was determined from the specific capsular reaction, using the encapsulated 
I- This was determined by using the autologous S .  aureus strain from each mouse. 
wound S .  aureus strain as test organism. 
the wound variant. Since the mice carried encapsulated S. aureus of the wound 
type and a significant number possessed capsular antibodies that reacted with 
this type, it was also postulated that the avirulence of the wound encapsulated 
strain could be explained on this basis. 
The studies that provided evidence for the possible existence of two distinct 
capsular types led to the isolation of 13 mucoid strains of S. aureus from mice. 
All were coagulase-positive and fermented mannitol anaerobically. Any of the 
mucoid strains that failed to react in the specific capsular reaction with anti- 
serum against the wound or Smith encapsulated S.  aureus strains were selected 
for the preparation of vaccine to be used to immunize rabbits. The results of 
specific capsular reaction tests carried out with homologous and heterologous 
antiserum are shown in TABLE 13. At least four capsular types were revealed 
by these tests. The wound mucoid strain, Smith diffuse strain, and naturally 
encapsulated mouse strains 36T and 43R appeared to be serologically distinct 
from each other. Strains designated as 47R, 50R, and 51R cross-reacted with 
antiserum against the 43R strain, and it was concluded that these strains were 
probably of the same capsular type as 43R. The wound mucoid strain is con- 
sidered to represent a major capsular type and has been isolated from humans 
and mice. Capsular antibodies against it have been detected in human, mouse, 
rabbit, and rooster sera. 
The four capsular types we proposed are the wound RLM type, a major 
type, the Smith diffuse type, and two serologically distinct types isolated from 
mice, designated as 36T and 43R. 
Virulence in an organism such as S. aureus is most likely multifactorial, 
but there is felt to be evidence that encapsulation is more common than is 
TABLE 12 
FURTHER STUDIES OF ANTlCAPSULAR ANTIBODIES ON 40 ADDITIONAL MOUSE SERA 
Test Strain Number Positive Percentage 
Smith diffuse * 0/40 0 
Wound mucoid I- 13/40 32.5 
* This was determined from the specific capsular reaction, using the encapsulated 
t This was determined from the specific capsular reaction, using the encapsulated 
Smith strain of S.  aureus. 
wound mucoid strain of S.  aureus. 
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generally accepted, and that the passive protective properties of antiserum or 
globulin that contains high titers of capsular antibodies provides evidence that 
the capsule contributes to virulence, particularly when absorption of these 
capsular antibodies by capsular polysaccharide significantly reduces the protec- 
tive properties of such antiserum. Whatever success we have had in relating 
virulence and encapsulation we attribute to the following: (1) to having a 
potent capsular antiserum, (2) to the use of young broth cultures of S. aureus 
for specific capsular reactions, and (3) to application of the specific capsular 
reaction to freshly isolated strains of S. aureus, which have been subcultured 
only once or twice. We can practise colonial selection, as workers with typhoid 
Vi antigen do  to maintain their cultures, but this works well only with the 
wound mucoid strain, because it is easy to recognize the mucoid trait. Naturally 
occurring encapsulated S. aureus strains are not necessarily highly mucoid, and 
subculture on ordinary laboratory media may result in the rapid loss of this 
trait. 
TABLE 13 
SPECIFIC APSULAR EACTIONS * OF ENCAPSULATED S.  aureus STRAINS 
Wound Smith 
Strain Mucoid Diffuse 36T 43R 47R 50R 51R 
- - - - - - 
- - - - - Wound mucoid + + Smith diuse - 
36T - - 
43R 
47R - - 
50R - - 
51R - - 
- - - - + + + + + 
- + + + + 
- + + + + 
- + + + + 
- - - 
*$ Antiserum produced by hyperimmunization of rabbits. 
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DISCUSSION OF THE PAPER 
DR. D. MIRELMAN: Do you know anything about the sensitivity to anti- 
biotics of the encapsulated strains? 
DR. WILEY: I don’t have the data. We do have antibiograms on these 
organisms. All I can say in an offhand way is that the antibiograms are repre- 
sentative of the antibiograms you would expect of those obtained from staphy- 
lococci isolated in hospitals. In other words, they have multiple antibiotic 
resistances. That statement doesn’t apply to those that occur naturally in 
animals, because I can’t make any statement about them. 
DR. M. TAGER: Once you have such a strain, are you able to maintain it 
easily in a laboratory, or does it tend to revert or lose its capsule? 
DR. WILEY: The wound strain is easy to maintain, as a number of people 
in this room know who have received cultures of this strain from me. Since 
its consistency is like that of chewing gum, when you touch a needle to it the 
whole colony comes up, and you can literally break your needle trying to shake 
the colony off into broth. 
The naturally occurring strains of encapsulated staphylococci are not of 
this character (I want to underline and emphasize this), and it is very difficult 
to maintain them. We now resort to lyophilization after the second subculture, 
and file them away, rather than risking loss of the capsular strain by subcultiva- 
tion. We don’t feel that we can be successful in colonial selection, because they 
do not always exhibit mucosity as our prototype wound strain does. 
DR. BENNETT (Food and Drug Administration, Washington, D.C.) : Out 
of the 21 carriers that were positive, what serological tests did you use to 
measure the anticapsular antibody? 
DR. WILEY: The test we use is the one that we’ve advocated as the most 
definitive test: that is, the specific capsular reaction. The old term is the 
Quellung reaction. 
DR. BENNETT: Have you used the hemagglutination inhibition test? 
DR. WILEY: No, we haven’t. We used the hemagglutination inhibition test 
only as a means of measuring the secretion of capsular material into the extra- 
cellular environment. This is a fairly cumbersome test, and we prefer screening 
with the specific capsular reaction. 
Actually, as Dr. Ekstedt said, it is a very simple procedure. Anyone can 
do it. One has a suspension of organisms; one simply puts a loop of organisms 
into a drop of antiserum and a drop of methylene blue, places a cover slip over 
them, waits a few minutes, and looks at them under a microscope. For screen- 
ing it’s simplicity itself. The difficult part is to get an antiserum with a high 
titer, but that can be done with vigorous immunization. 
